Should healthy adults get a screening ECG?

For an adult with no symptoms and a low risk of heart disease, US preventive guidance recommends against having a screening electrocardiogram, whether at rest or on a treadmill [s1]. For those at intermediate or high risk it does not endorse the test either — it concludes the evidence is insufficient to say whether the ECG adds anything useful [s1]. The blunt reason is that the tracing seldom tells a doctor something that changes the treatment a person should already be getting.

An ECG records the heart's electrical activity, and in someone with chest pain, palpitations or breathlessness it is indispensable. Screening is the different question of running it on people who feel well, in the hope of catching hidden trouble early. Whether that hope is borne out is what the US Preventive Services Task Force set out to test when it updated its recommendation in 2018 [s1].

What the evidence review found

The Task Force's accompanying evidence report pooled 16 studies covering 77,140 people [s2]. The strongest design available was sparse: only two randomised trials, together enrolling 1,151 adults aged 50 to 75 with diabetes, had tested exercise-ECG screening against no screening, and neither found a significant benefit for the main cardiovascular outcome (hazard ratios 1.00, 95% confidence interval 0.59 to 1.71, and 0.85, 95% confidence interval 0.39 to 1.84) [s2]. No randomised trial had ever tested resting-ECG screening at all [s2].

The rest of the evidence came from cohort studies asking a narrower question: does adding an ECG to the standard risk factors sharpen the prediction of who will have a heart event? The answer was "barely." Adding exercise ECG improved discrimination — the statistical ability to separate those who will have an event from those who will not — by an absolute 0.02 to 0.03 on a scale where 1.0 is perfect (three studies) [s2]. Adding resting ECG improved it by 0.001 to 0.05 across nine cohort studies of 66,407 people [s2]. These are small gains, and whether they translate into better decisions or fewer heart attacks is uncertain [s2].

Why a tiny gain becomes a net harm

If the upside is marginal, the downside is concrete. An abnormal-looking tracing in a well person tends to trigger further tests — stress imaging, angiography — and those downstream procedures carry their own risks, from the merely inconvenient to the genuinely dangerous [s1] [s2]. Because most symptom-free people are not, in fact, harbouring significant disease, a large share of the abnormalities a screening ECG turns up are false alarms or findings that would never have caused trouble. The Task Force's arithmetic is that for low-risk adults these harms outweigh a benefit it could not detect, which is why the recommendation there is a firm "against" (a D recommendation) [s1]. For intermediate- and higher-risk adults it stops short of that and issues an "insufficient evidence" statement, meaning the balance simply cannot be determined from what has been studied [s1].

There is a subtler point underneath. Treatment to prevent heart disease is already guided by risk calculators such as the Pooled Cohort Equations, which combine age, sex, smoking, cholesterol, blood pressure and diabetes [s1] [s2]. For the ECG to earn its place it would have to move a person into a different risk category often enough to change what is done — a higher bar than merely being "abnormal," and one the evidence does not clear [s1].

Where the cardiology guidance lands

This is a case where the specialist and preventive bodies broadly agree rather than clash. The 2019 American College of Cardiology and American Heart Association guideline on primary prevention builds care around the same quantitative risk estimation, and does not call for routine screening ECGs in asymptomatic adults [s3]. Where it offers a further test, it is a different one: coronary artery calcium scoring, which it presents as an option to refine risk in selected intermediate-risk adults when a treatment decision is genuinely uncertain [s3]. The disagreement, such as it is, is about which supplementary test might occasionally help — not about whether a blanket screening ECG is worth doing.

What it means for a reader

A screening ECG in a person without symptoms is not recommended at low risk and is unproven at higher risk, and it can start a cascade of testing that does more harm than good [s1] [s2]. That verdict sits alongside the same reasoning the Task Force applies to other "just in case" scans of the symptom-free — the case-by-case logic of carotid screening and of aortic-aneurysm screening, where who benefits is defined narrowly. It is also worth separating from the single-lead ECG now built into smartwatches, which is aimed at detecting an irregular rhythm, not at estimating heart-attack risk. None of this touches symptoms: chest pain, fainting or a racing heart is a reason to be examined, and there the ECG does its real job.